Quest for the right Drug
פבוקסיל 100 FAVOXIL 100 (FLUVOXAMINE MALEATE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליה : TABLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Pharmacological properties : תכונות פרמקולוגיות
Pharmacodynamic Properties
5.1 Pharmacodynamic properties Pharmacotherapeutic group: Antidepressants, Selective serotonin reuptake inhibitors ATC code: N06AB08 The mechanism of action of fluvoxamine is thought to be related to selective serotonin re-uptake inhibition in brain neurones. There is minimum interference with noradrenergic processes. Receptor binding studies have demonstrated that fluvoxamine has negligible binding capacity to alpha adrenergic, beta adrenergic, histaminergic, muscarine cholinergic, dopaminergic or serotonergic receptors. In a placebo controlled trial in 120 patients with OCD, aged between 8 and 17 years, a statistically significant improvement was seen in the total population in favour of fluvoxamine at 10 weeks. A further subgroup analysis showed improvement on the C- YBOCS rating scale in children whereas no effect was seen in adolescents. The mean dose was respectively 158 mg and 168 mg/day. Dose response No formal clinical trials were conducted investigating the dose response of fluvoxamine. However, it is clinical experience that up-titrating the dose might be beneficial for some patients.
Pharmacokinetic Properties
5.2 Pharmacokinetic properties Absorption Fluvoxamine is completely absorbed following oral administration. Maximum plasma concentrations occur within 3-8 hours of dosing. The mean absolute bioavailability is 53% due to first-pass metabolism. The pharmacokinetics of fluvoxamine is not influenced by concomitant food intake. Distribution In vitro plasma protein binding of fluvoxamine is 80%. Volume of distribution in humans is 25 l/kg. Metabolism Fluvoxamine undergoes extensive metabolism in the liver. Although CYP2D6 is in vitro the main isoenzyme involved in fluvoxamine’s metabolism, plasma concentrations in poor metabolisers for CYP2D6 are not much higher than those in extensive metabolisers. The mean plasma half-life is approximately 13-15 hours after a single dose and slightly longer (17-22 hours) during repeated dosing,when steady-state plasma levels are usually achieved within 10-14 days. Fluvoxamine undergoes extensive hepatic transformation, mainly via oxidative demethylation, into at least nine metabolites, which are excreted by the kidneys. The two major metabolites showed negligible pharmacological activity. The other metabolites are not expected to be pharmacologically active. Fluvoxamine is a potent inhibitor of CYP1A2 and CYP2C19. A moderate inhibition was found for CYP2C9, CYP2D6 and CYP3A4. Fluvoxamine displays linear single-dose pharmacokinetics. Steady-state concentrations are higher than calculated from single-dose data, and this disproportional increase is more pronounced with higher daily doses. Special Patients groups The pharmacokinetics of fluvoxamine is similar in healthy adults, elderly patients, and patients with renal insufficiency. The metabolism of fluvoxamine is impaired in patients with liver disease. Steady-state plasma concentrations of fluvoxamine were twice as high in children (aged 6-11) as in adolescents (aged 12-17). Plasma concentrations in adolescents are similar to those in adults.
שימוש לפי פנקס קופ''ח כללית 1994
Depressive illness. יירשם ע"י רופא פסיכיאטר ורופא עצבים
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת
רישום
041 91 25728 00
מחיר
0 ₪
מידע נוסף
עלון מידע לצרכן
14.10.21 - עלון לצרכן אנגלית 14.10.21 - עלון לצרכן עברית 14.10.21 - עלון לצרכן ערבית 19.09.22 - עלון לצרכן עברית 27.02.23 - עלון לצרכן אנגלית 27.02.23 - עלון לצרכן עברית 27.02.23 - עלון לצרכן ערבית 23.01.24 - עלון לצרכן עברית 18.09.24 - עלון לצרכן אנגלית 19.09.24 - עלון לצרכן עברית 18.09.24 - עלון לצרכן ערבית 13.12.11 - החמרה לעלון 18.01.12 - החמרה לעלון 05.06.13 - החמרה לעלון 21.01.15 - החמרה לעלון 22.02.17 - החמרה לעלון 11.01.18 - החמרה לעלון 06.08.20 - החמרה לעלון 14.10.21 - החמרה לעלון 19.09.22 - החמרה לעלון 11.04.24 - החמרה לעלוןלתרופה במאגר משרד הבריאות
פבוקסיל 100